Torrent Pharmaceuticals is back in the spotlight after JPMorgan upgraded the stock to Overweight and lifted its price target to ₹3,800 from ₹3,650. The news sent the stock climbing as much as 4.5 percent on Friday, briefly hitting ₹3,371.45, its highest intraday level in over a month.
The brokerage’s revised target implies a 17.8 percent upside from Thursday’s close at ₹3,225.70. At last check, shares were trading at ₹3,330, up 3.34 percent on the day, outpacing the BSE Sensex, which was up 0.28 percent.
Why the Upgrade?
JPMorgan’s bullish turn centers on Torrent’s domestic growth engine. India operations, which contributed the lion’s share of Q4 results, are expected to maintain momentum across core therapeutic segments. The firm also cited Torrent’s consistent execution and improving margins as supportive of a higher valuation band.
Torrent Pharma Q4 Results
Torrent Pharma’s Q4 FY25 earnings were solid. Consolidated net profit rose 11 percent year-on-year to ₹498 crore, while revenue grew 8 percent to ₹2,959 crore. The performance was once again led by strong traction in India, reaffirming its position as a reliable earnings anchor.
Chart Levels to Watch
- Current price: ₹3,330.00
- Resistance: ₹3,375.00, then ₹3,400.00
- Support: ₹3,287.00, then ₹3,200.00
Outlook
Torrent Pharma’s upgrade from JPMorgan isn’t just a headline, it’s a vote of confidence in the company’s long-term positioning. As India’s pharma sector enters a fresh growth cycle, Torrent’s strong domestic footing and healthy balance sheet give it an edge. If the ₹3,400 level clears, bulls may aim for the full ₹3,800 target sooner than expected.
This article is also available in: Polski, Nederlands, हिन्दी, Deutsch, Italiano, Español, Türkçe.
The post Torrent Pharma Surges 4.51% After JPMorgan Upgrade, Target Raised to ₹3,800 appeared first in UK on InvestingCube.